Details for Patent: 11,771,701
✉ Email this page to a colleague
Which drugs does patent 11,771,701 protect, and when does it expire?
Patent 11,771,701 protects JYLAMVO and is included in one NDA.
This patent has twenty-three patent family members in eighteen countries.
Drugs Protected by US Patent 11,771,701
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE | ⤷ Sign Up | |||
| Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE | ⤷ Sign Up | |||
| Shorla | JYLAMVO | methotrexate | SOLUTION;ORAL | 212479-001 | Nov 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,771,701
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015340373 | ⤷ Sign Up | |||
| Canada | 3002493 | ⤷ Sign Up | |||
| China | 107106485 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
